SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) Share Price Rises 8.96% Today

SURAKSHA DIAGNOSTIC LIMITED Share Price moved sharply higher on 10 August 2026, rising 8.96% to Rs 272.5 from the previous close of Rs 250.1, lifting the company’s market capitalisation to Rs 1,302.54 crore. For readers tracking SURAKSHA DIAGNOSTIC LIMITED Share Price Today, the move stands out because the stock has qualified under the workflow’s price rise screen for its Small Cap category, placing it among the day’s top gainers in Healthcare names.

The supplied data confirms what happened in the market: the stock opened at Rs 249.05, touched an intraday high of Rs 272.7, and held well above the session low of Rs 249.05. That means the day’s strength was not just a brief spike from the open; the price extended meaningfully above the previous close as trading progressed. On the turnover side, traded value stood at Rs 0.17 crore, while total volume across exchanges reached 66,656 shares.

For anyone searching SURAKSHA DIAGNOSTIC LIMITED Stock News, the important point is that the verified data establishes the price rise clearly, but it does not establish a company-specific catalyst behind today’s move. Even so, the combination of a notable share price gain, a Rs 1,302.54 crore market cap and valuation metrics such as a P/E ratio of 40.47 and P/B ratio of 5.32 makes this a stock worth monitoring. In this Univest review, the focus is on the day’s price action, fundamental context, sector positioning and peer comparison rather than speculation about causes.

SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 272.5
Previous Close	Rs 250.1
Today's Change	+Rs 22.4 (+8.96%)
Day Open	Rs 249.05
Day High	Rs 272.7
Day Low	Rs 249.05
Current Volume (BSE)	6,355
BSE Traded Volume	6,355
NSE Traded Volume	60,301
Combined NSE + BSE Volume	66,656
Turnover	Rs 0.17 crore
Market Capitalisation	Rs 1,302.54 crore
Market Cap Category	Small Cap

SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) traded at Rs 272.5. versus the previous close of Rs 250.1, a rise of 8.96%. The stock opened at Rs 249.05, reached Rs 272.7, touched Rs 249.05. Reported volume was 6,355.

SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,302.54 crore
P/E Ratio	40.47x
P/B Ratio	5.32x
ROE	13.93%
ROCE	22.94%
EPS	Rs 6.18
Dividend Yield	0.2%

SURAKSHA DIAGNOSTIC LIMITED was valued at a P/E ratio of 40.47x, a P/B ratio of 5.32x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 13.93% and ROCE of 22.94%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 6.18, dividend yield of 0.2%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

SURAKSHA DIAGNOSTIC LIMITED Share Price is drawing attention, but the supplied fundamentals show a more layered picture than price alone. At a market capitalisation of Rs 1,302.54 crore, the company sits in the small-cap bracket, which speaks to size rather than business quality. On valuation, the stock trades at a P/E ratio of 40.47 and a P/B ratio of 5.32. Those are meaningful numbers because they indicate how the market is pricing the company’s earnings and accounting net worth relative to many other listed healthcare service businesses.

Profitability metrics offer useful context. Return on equity, or ROE, stands at 13.93%, while ROCE is 22.94%. That gap suggests the business is generating a stronger return on capital employed than on shareholder equity alone, which is relevant when assessing operational efficiency. The earnings per share, or EPS, is Rs 6.18, showing the earnings attributable to each share. Dividend yield is 0.2, which indicates a modest historical payout relative to the current market price and should be read as a current data point rather than a future payout signal.

When SURAKSHA DIAGNOSTIC LIMITED Share Price Rise is viewed against these figures, the valuation appears richer than many broad-market small caps, but the company is also not being priced on weak return metrics alone. A P/B of 5.32 is notably above many lower-multiple healthcare names, while ROE of 13.93% and ROCE of 22.94% indicate that the market is attaching value to operating returns. The stock’s current price of Rs 272.5 also means investors are paying a premium to the annualised earnings base reflected by the EPS number.

For readers seeking SURAKSHA DIAGNOSTIC LIMITED Fundamental Analysis, the practical takeaway is balanced. The stock combines positive return ratios with a valuation that is not obviously cheap on standalone numbers. That does not define whether the stock should continue rising or cool off, but it does explain why today’s move is likely to keep market participants focused on quality, valuation discipline and sector context. From here, the next step is to compare those fundamentals with the company’s industry benchmark.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Hospital & Healthcare Services
Benchmark Scope	same industry
Company P/E Ratio	40.47x
Benchmark Median P/E	32.6x
Benchmark Average P/E	160.94x
Benchmark P/E Range	7.43x to 2,997.5x
Company P/B Ratio	5.32x
Benchmark Median P/B	1.88x
Company ROE	13.93%
Benchmark Median ROE	13.45%
Company ROCE	22.94%
Benchmark Median ROCE	17.15%
Company Market Capitalisation	Rs 1,302.54 crore
Benchmark Median Market Cap	Rs 94.41 crore

SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) is classified under sector: Healthcare and industry: Hospital & Healthcare Services.

SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) has a P/E ratio of 40.47x, which is above the benchmark median of 32.6x, a difference of +24.14%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) has a ROE of 13.93%, which is above the benchmark median of 13.45%, a difference of +3.57%. SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) has a ROCE of 22.94%, which is above the benchmark median of 17.15%, a difference of +33.76%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

SURAKSHA DIAGNOSTIC LIMITED Share Price is best understood in the context of the Healthcare sector and the Hospital & Healthcare Services industry, where the supplied benchmark covers 42 companies in the same industry. On a market basis, this is a relatively sizeable player versus that group: the company’s market cap of Rs 1,302.54 crore stands well above the benchmark median of Rs 94.41 crore and above the benchmark average of Rs 427.06 crore, though below the maximum of Rs 2,537.93 crore.

Valuation tells a more nuanced story. The company’s P/E ratio is 40.47. That is above the industry median P/E of 32.6 but far below the industry average of 160.94, which is influenced by a very wide range from 7.43 to 2,997.5 across 34 companies with available P/E data. In other words, SURAKSHA DIAGNOSTIC LIMITED Share Price does not screen as low valuation relative to the median, but neither does it sit at an extreme when viewed against the full spread of listed peers.

On price-to-book, the company’s P/B ratio of 5.32 is materially above the benchmark median of 1.88 and the benchmark average of 1.89 across 42 companies. That implies the stock commands a premium to book value within its industry group. Profitability partly offsets that premium. ROE of 13.93% is slightly above the benchmark median of 13.45%, though well below the benchmark average of 34.25%. ROCE of 22.94% is stronger, standing above the benchmark median of 17.15% and above the benchmark average of 20.39%.

For investors reading SURAKSHA DIAGNOSTIC LIMITED Stock Analysis, this sector comparison matters. The stock is not the cheapest on either earnings or book multiples, but its return on capital employed compares favourably with the same-industry benchmark. Univest therefore sees today’s price rise as a market event worth tracking within a healthcare services basket where both valuation dispersion and profitability dispersion are wide.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,537.93	33.3	6.87	-2.6	16.92
KMC Speciality Hospitals (India) Ltd.	KMCSHIL	1,948.05	41.68	9.26	22.42	25.85
Krsnaa Diagnostics Ltd.	KRSNAA	1,831.49	18.06	1.87	0	129.09
Shalby Ltd.	SHALBY	1,733.02	46.35	1.72	5.19	6.85
GPT Healthcare Ltd.	GPTHEALTH	1,299.75	27.5	4.61	33.06	25.56

SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) has a P/E ratio of 40.47x compared with the displayed peer median of 33.3x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 13.93% compares with a peer median of 5.19% across the companies shown in the table. ROCE stood at 22.94% versus the displayed peer median of 25.56%, providing a capital-efficiency comparison. SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) has a market capitalisation of Rs 1,302.54 crore. Among the 5 peers shown, 4 have a larger market capitalisation.

SURAKSHA DIAGNOSTIC LIMITED Share Price also gains context when measured against specific listed peers in Hospital & Healthcare Services. In market-cap terms, the company at Rs 1,302.54 crore sits very close to GPT Healthcare Ltd. at Rs 1,299.75 crore, below Shalby Ltd. at Rs 1,733.02 crore, Krsnaa Diagnostics Ltd. at Rs 1,831.49 crore and KMC Speciality Hospitals (India) Ltd. at Rs 1,948.05 crore, but above Unihealth Hospitals Ltd. at Rs 1,230.66 crore, GUJARAT KIDNEY N SUP SP L at Rs 1,059.65 crore, GAUDIUM IVF N WOMEN H L at Rs 953.51 crore and KRM Ayurveda Ltd. at Rs 642.08 crore.

On valuation, the company’s P/E ratio of 40.47 is higher than Dr Agarwals Eye Hospital Ltd. at 33.3, Krsnaa Diagnostics at 18.06, GPT Healthcare at 27.5 and KRM Ayurveda at 31.91. It is lower than KMC Speciality Hospitals at 41.68, Shalby at 46.35, Unihealth Hospitals at 47.64 and GUJARAT KIDNEY N SUP SP L at 68.38. Against GAUDIUM IVF N WOMEN H L at 38.98, it is only slightly higher. That places SURAKSHA in the middle-to-upper end of peer earnings multiples rather than at an outlier level.

Profitability comparisons are similarly mixed. ROE of 13.93% is stronger than Dr Agarwals Eye Hospital’s -2.6%, Krsnaa Diagnostics’ 0 and Shalby’s 5.19%, but below KMC Speciality Hospitals at 22.42%, GPT Healthcare at 33.06%, Unihealth Hospitals at 29.75%, GUJARAT KIDNEY N SUP SP L at 26.56%, GAUDIUM IVF N WOMEN H L at 94.99% and KRM Ayurveda at 90.82%. On ROCE, SURAKSHA’s 22.94% is above Dr Agarwals Eye Hospital at 16.92, Shalby at 6.85 and Unihealth Hospitals at 20.33, but below KMC Speciality Hospitals at 25.85, GPT Healthcare at 25.56, GUJARAT KIDNEY N SUP SP L at 36.31, KRM Ayurveda at 37.67, GAUDIUM IVF N WOMEN H L at 82.39 and Krsnaa Diagnostics at 129.09.

The broad conclusion from this peer set is that SURAKSHA DIAGNOSTIC LIMITED Share Price is supported by respectable profitability, but the stock is not a clear low-multiple bargain within the peer universe. For investors following SURAKSHA DIAGNOSTIC LIMITED Latest News, the peer data suggests a business that is competitively positioned in size yet still demands careful valuation monitoring.

Why Investors Are Watching SURAKSHA DIAGNOSTIC LIMITED

SURAKSHA DIAGNOSTIC LIMITED Share Price is being watched because today’s 8.96% move is large enough to make the stock a visible market mover while the underlying financial ratios offer both support and caution. The stock is part of the Healthcare space, has a market cap of Rs 1,302.54 crore and trades at valuation multiples that sit above industry medians in some areas. That makes it relevant for both short-term price action tracking and longer-horizon stock analysis on Univest.

• Verified price action: the stock rose Rs 22.4 to Rs 272.5 from Rs 250.1, after opening at Rs 249.05 and touching Rs 272.7.
• Volume footprint: total volume reached 66,656 shares, with 60,301 on NSE and 6,355 on BSE, alongside turnover of Rs 0.17 crore.
• Fundamental context: P/E stands at 40.47, P/B at 5.32, ROE at 13.93%, ROCE at 22.94%, EPS at Rs 6.18 and dividend yield at 0.2.
• Sector positioning: P/E is above the same-industry median of 32.6, while ROCE is above the benchmark median of 17.15 and average of 20.39.
• Peer relevance: the company’s market cap is close to GPT Healthcare, while valuation and return metrics sit in the mid-range of listed peers.

What investors may monitor next is whether SURAKSHA DIAGNOSTIC LIMITED Share Price sustains this move around the day high zone after such a quick re-rating in live trade. In the absence of a verified company-specific catalyst in the supplied data, attention is likely to remain on follow-through in price, relative valuation versus healthcare peers and whether the stock continues to command a premium within its industry basket. That is where Univest readers can separate a one-day move from a broader market reappraisal.

About SURAKSHA DIAGNOSTIC LIMITED

SURAKSHA DIAGNOSTIC LIMITED operates in the Healthcare sector and is classified within the Hospital & Healthcare Services industry. That industry placement is important because it frames how the market evaluates the company: investors generally compare such businesses through a combination of scale, profitability, earnings multiples and return ratios rather than through commodity-style pricing metrics.

Based on the supplied classification, SURAKSHA DIAGNOSTIC LIMITED is part of a listed universe of healthcare service companies that includes hospitals, diagnostics-focused operators and other patient-service platforms. In market-cap terms, the company at Rs 1,302.54 crore is well above the industry median and also above the industry average supplied in the benchmark snapshot. That suggests it is not a fringe micro business within the listed healthcare services space, even though it remains a Small Cap by market-cap category under the event framework.

For readers looking for SURAKSHA DIAGNOSTIC LIMITED Company News or SURAKSHA DIAGNOSTIC LIMITED Market Cap context, the most relevant business takeaway is that the company sits in an industry where valuation dispersion is very wide and profitability also varies sharply from one listed name to another. That means stock performance can often be judged against peers on metrics such as P/E, P/B, ROE and ROCE rather than on price movement alone. In practical terms, today’s move puts greater attention on how SURAKSHA compares within the broader Hospital & Healthcare Services pack tracked by Univest.

Track SURAKSHA DIAGNOSTIC LIMITED Share Price on Univest

Use SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

SURAKSHA DIAGNOSTIC LIMITED Share Price can be tracked on Univest for live price updates, market cap changes, valuation ratios and broader stock analysis. Users following SURAKSHA DIAGNOSTIC LIMITED Share Price Today can monitor current price movement alongside indicators such as P/E ratio, P/B ratio, ROE, ROCE, EPS and dividend yield, as well as 52-week market context when available in the platform dataset.

Univest also helps readers track SURAKSHA DIAGNOSTIC LIMITED Stock News, compare the company with listed peers in Healthcare and review data-led market insights without relying on speculation. For investors who prefer a structured view of price action, fundamentals and sector ranking in one place, SURAKSHA DIAGNOSTIC LIMITED Share Price coverage on Univest offers a useful starting point for ongoing monitoring.

Frequently Asked Questions

Why is SURAKSHA DIAGNOSTIC LIMITED Share Price rising today?

Ans. SURAKSHA DIAGNOSTIC LIMITED Share Price rose because the stock moved 8.96% higher to Rs 272.5 from the previous close of Rs 250.1. The supplied data confirms the price event, but it does not establish a company-specific catalyst behind today’s move.

What is SURAKSHA DIAGNOSTIC LIMITED Share Price Today?

Ans. SURAKSHA DIAGNOSTIC LIMITED Share Price Today is Rs 272.5 at the time captured in the supplied data. The stock gained Rs 22.4 in absolute terms, after trading between an intraday low of Rs 249.05 and a high of Rs 272.7.

How much did SURAKSHA DIAGNOSTIC LIMITED stock gain today?

Ans. The stock gained Rs 22.4 in one session, which translates into an 8.96% rise over the previous close of Rs 250.1. That move was large enough to place the company among notable top gainers tracked under the price rise event.

What does today’s price action show for SURAKSHA DIAGNOSTIC LIMITED?

Ans. Today’s price action shows the stock opened at Rs 249.05, which was also the day’s low, and then climbed to Rs 272.7 before trading at Rs 272.5. That pattern indicates sustained upward movement rather than a brief opening spike.

What is the market capitalisation of SURAKSHA DIAGNOSTIC LIMITED?

Ans. SURAKSHA DIAGNOSTIC LIMITED has a market capitalisation of Rs 1,302.54 crore in the supplied data. It is classified as a Small Cap stock under the event framework, while still being larger than the same-industry market-cap median of Rs 94.41 crore.

How active was trading in SURAKSHA DIAGNOSTIC LIMITED today?

Ans. Total traded volume stood at 66,656 shares, with 60,301 shares on NSE and 6,355 shares on BSE. The reported turnover was Rs 0.17 crore, showing that today’s share price rise was accompanied by measurable market participation.

Is SURAKSHA DIAGNOSTIC LIMITED expensive compared with its industry P/E?

Ans. The stock’s P/E ratio is 40.47, which is above the same-industry median of 32.6 but below the industry average of 160.94. That means the valuation is richer than the median healthcare services stock, though not extreme within the full benchmark.

How does SURAKSHA DIAGNOSTIC LIMITED compare on profitability?

Ans. The company’s ROE is 13.93% and ROCE is 22.94%. ROE is slightly above the same-industry median of 13.45%, while ROCE is above both the benchmark median of 17.15% and average of 20.39% in the supplied dataset.

What are the key fundamental metrics of SURAKSHA DIAGNOSTIC LIMITED?

Ans. Key metrics include a P/E ratio of 40.47, P/B ratio of 5.32, ROE of 13.93%, ROCE of 22.94%, EPS of Rs 6.18 and dividend yield of 0.2. Together, these figures frame the stock’s valuation and operating return profile.

How does SURAKSHA DIAGNOSTIC LIMITED compare with peers?

Ans. The company’s market cap of Rs 1,302.54 crore is close to GPT Healthcare’s Rs 1,299.75 crore. Its P/E of 40.47 is below Shalby’s 46.35 and Unihealth’s 47.64, but above GPT Healthcare’s 27.5 and Krsnaa Diagnostics’ 18.06.